Article
Ablation of toll-like receptor 4 mitigates cardiac mitochondrial dysfunction in hyperhomocysteinemia.
Canadian journal of physiology and pharmacology - 1 Nov 2017
Jeremic Nevena, Weber Gregory J, Tyagi Suresh C
Abstract excerpt
Hyperhomocysteinemia (HHcy) is a risk factor for adverse cardiovascular events; however, the mechanism for development of this disease is still unknown. Toll-like receptor 4 (TRL4) is a molecule involved in the immune response pathway and is quickly becoming a receptor of interest in the field of hypertension. In this study, we hypothesized that ablation of TLR4 mitigates cardiac mitochondrial dysfunction in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
